FDA has approved an aggressive stem cell clinical trial, offering potential new relief through intravenous (IV) administration. HENDERSON, Nev., May 13, 2025 /PRNewswire-PRWeb/ — “We at L2 Bio thank the FDA for what we believe is a very aggressive approval in the fight against Crohn’s…
L2 Bio, FDA Approves Crohn's Disease Trial as a Phase 2b Utilizing Adipose-Derived Stem Cells
This post was originally published on this site